CVS stock fell by 14% on January 27 after the CMS revealed a modest 0.09% rate increase for 2027, which was a considerable disappointment compared to investor predictions of 4-6%. Although CVS's 14% drop was significant, it was not as severe as the over 20% declines seen at UnitedHealth and Humana.
Shares of several big-name health care companies plunged after the Trump administration proposed nearly flat rates for Medicare Advantage insurers. In extended trading, Humana, CVS Health and UnitedHealth Group saw their shares slide by more than 10%.
CVS Health (CVS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
CVS Health (CVS) concluded the recent trading session at $82.68, signifying a +1.46% move from its prior day's close.
CVS Health (CVS) closed at $81.36 in the latest trading session, marking a +2.56% move from the prior day.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Recently, Zacks.com users have been paying close attention to CVS Health (CVS). This makes it worthwhile to examine what the stock has in store.
CVS Health (CVS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
CVS Health (CVS) closed at $79.79 in the latest trading session, marking a -1.13% move from the prior day.
Recently, Zacks.com users have been paying close attention to CVS Health (CVS). This makes it worthwhile to examine what the stock has in store.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.